STXS Stock: Why It Increased This Past Week

By Amit Chowdhry ● Oct 14, 2021
  • The stock price of Stereotaxis Inc (NYSEAMERICAN: STXS) has seen an uptick this week. This is why it happened.

The stock price of Stereotaxis Inc (NYSEAMERICAN: STXS) – a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias – has seen an uptick this week. Investors are responding positively to Stereotaxis announcing a publication in the International Journal of Cardiology: Heart & Vascular demonstrating superior safety and efficacy of Stereotaxis’ robotic technology to treat atrioventricular reentry tachycardia (AVRT) and atrioventricular nodal reentry tachycardia (AVNRT) in pediatric patients with heart rhythm disease. 

The 223-patient study – conducted at Erasmus Medical Center in Rotterdam, the Netherlands – compared Robotic Magnetic Navigation (RMN) guided cardiac ablation to manual radiofrequency (RF) ablation and manual cryoablation.

The study’s primary endpoint was long-term freedom from arrhythmia recurrence with a mean follow-up time of 5.5 years. AV(N)RTs cause abnormally fast heartbeats and are the most common supraventricular tachyarrhythmias (SVT) in children without structural heart disease. And left untreated, frequent episodes may weaken the heart and lead to heart failure. Median age of patients in the study was 14 years at the time of treatment. 

Patients treated with RMN had 94.4% freedom from arrhythmia recurrence through long-term follow-up, compared to only 85.5% and 59% in patients treated with manual RF ablation or cryoablation, respectively (p<0.01).

While cardiac ablation is a common treatment for AV(N)RT, there is risk of procedural complications and the impact of procedural radiation on pediatric patients is a concern. And in this study, patients who received catheter ablation with RMN experienced zero adverse events, compared with a 2.6% rate of adverse events for manual RF ablation and 2.6% for cryoablation. X-ray exposure was lowest in the RMN procedures, with exposure being 34% and 38% higher with manual RF ablation and cryoablation procedures, respectively.

KEY QUOTES:

“We are excited to share data from this large long-term comparative study. It builds upon the significant body of evidence supporting the clinical value of robotics for arrhythmia patients, particularly the most vulnerable patients with complex disease.”

— Dr. Anne-Marie Noten, author of the publication

“Particularly in small hearts, the flexibility and versatility of a magnetic catheter with Stereotaxis allows us to perform cardiac ablation without being limited to fixed, pre-defined curves. The stability and precision of robotics enables us to provide the best care for our patients. We are proud to advance the frontiers of patient care and the scientific knowledge in electrophysiology, particularly when we can improve the health of children we are entrusted to treat.”

— Dr. Tamas Szili-Torok, cardiac electrophysiologist and associate professor at Erasmus Medical Center

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.